Samuel Kintz, PRESIDENT AND CEO at Enliven Therapeutics, Inc. (ELVN), sold 23,900 shares at $22.86 ($554K) on 2024-05-28, disclosed to the SEC on 2024-05-30.
Scheduled sale ($554k) by PRESIDENT AND CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $22.86 | 6,681 | $153K | 27.6% |
| 2 | $22.86 | 6,681 | $153K | 27.6% |
| 3 | $23.57 | 5,219 | $123K | 22.2% |
| 4 | $23.57 | 5,219 | $123K | 22.2% |
| 5 | $24.34 | 100 | $2K | 0.4% |
| Total | $23.18 avg | 23,900 |
| $554K |
| 100% |
| Filing → |
| ELVN | SELL | 2025-09-30 | $74K | — | Filing → |
| ELVN | SELL | 2025-09-25 | $56K | — | Filing → |
| ELVN | SELL | 2025-09-19 | $116K | — | Filing → |